Magnolia Diagnostics, Owners, and Investors to Pay $24M Over Medicare Fraud for Unnecessary COVID-19 Tests

The Alleged Tying of COVID-19 Tests to Unnecessary Respiratory Panels

During the early months of the pandemic, Magnolia Diagnostics developed a strategy to boost revenue by requiring senior living communities to purchase expensive respiratory pathogen panels (RPPs) if they wanted COVID-19 tests. The lab allegedly used pre-filled requisition forms already selecting RPP testing and associated diagnosis codes — before any clinician had assessed an individual patient. Provider signatures on those forms were then treated as standing orders authorizing RPPs for entire communities or chains of senior residences.

The government further claims that Magnolia kept performing the panels even after providers and facilities demanded COVID-19-only testing, questioned the medical necessity of the panels, or stated they had never authorized them. In some instances, co-owner John Bains allegedly threatened to withhold COVID-19 testing altogether if communities refused the bundled panels. He is also accused of altering a provider-signed form to expand its apparent authorization to multiple facilities not covered by the original document.

The lab stored thousands of respiratory specimens, sometimes for weeks or months, before thawing and testing them. That produced RPP results long after they could guide timely treatment, isolation, or infection-control decisions. Between April 2020 and September 2021, Magnolia and its owners knowingly submitted, or caused the submission of, thousands of false claims to Medicare for medically unnecessary tests, according to the Justice Department.

Magnolia and the Bainses have agreed to pay $19.2 million to resolve the False Claims Act allegations. Investors who received distributions from the lab will pay an additional $4.8 million to settle claims for unjust enrichment and payment by mistake. Officials from the Justice Department and the Department of Health and Human Services stressed that they will pursue not only companies and executives but also investors who reap the financial benefits of healthcare fraud.

The DOJ's Strategy: Going After Owners, Investors, and Altered Forms

Investor Liability: A Warning Shot

The $4.8 million paid by investors marks a significant extension of enforcement. Typically, settlement figures are borne by the entity and its operating managers. Here, the DOJ explicitly targeted distributions that flowed to investors — a signal that passive capital is no longer insulated when it profits from fraudulent billing. The government used common law claims of unjust enrichment to reach those funds, a tool that could become more common in future healthcare fraud resolutions.

Altered Forms and Standing Orders: Evidence of Deliberate Conduct

The allegation that John Bains altered a provider-signed requisition form to expand its coverage to additional facilities is particularly damaging. It moves the case beyond a billing error or ambiguous medical necessity into territory that suggests intentional falsification. Combined with the use of prepopulated forms — where RPPs were preselected before any clinician saw a patient — the details paint a picture of a deliberate, top-down revenue strategy rather than isolated lapses.

Ramping Up the False Claims Act Under New Fraud Task Forces

The settlement aligns with the Trump administration’s recent creation of the Task Force to Eliminate Fraud and the National Fraud Enforcement Division. The Civil Division’s Commercial Litigation Branch, Fraud Section, worked jointly with the U.S. Attorney’s Office for the Northern District of Texas. This case highlights that COVID-19-era fraud remains a priority, and the Justice Department is willing to pursue civil recoveries well beyond the public-health emergency itself.

What the Case Means for Laboratories and Senior Living Facilities

For diagnostic labs, the case underscores that tying COVID-19 testing — a must-have service during the pandemic — to revenue-boosting add-on panels invites scrutiny. For senior living operators, the lesson is stark: blanket standing orders that authorize broad testing without individualized clinical review can expose both the provider and the facility to risk. Operators should review their contracts with testing labs, ensuring that every test billed to Medicare is supported by a contemporaneous, patient-specific determination of medical necessity.

What Labs and Senior Facilities Can Learn from Magnolia's Fallout

• Physician orders for respiratory testing must be specific to each patient and encounter; blanket standing orders for entire communities are highly likely to attract False Claims Act scrutiny.
• Labs should audit their requisition forms to confirm that no test is pre-selected before a clinician’s assessment — prepopulated RPP codes were central to the allegations against Magnolia.
• Senior living operators should revisit all contractual arrangements with testing providers. If bundled COVID-19 and RPP testing was implemented without informed consent or clear medical necessity for each resident, the arrangement may carry compliance risk.
• Investors — including private equity and venture capital firms in healthcare — must now factor in potential clawback risk. The DOJ’s recovery of $4.8 million from passive investors signals that receiving distributions from a fraudulent enterprise can lead to direct financial liability.
• Compliance programs should specifically flag the tactic of freezing specimens and testing them later, because it undercuts the clinical value of the result and can become an aggravating factor in a government investigation.